ClinVar Miner

Submissions for variant NM_000249.3(MLH1):c.1502T>G (p.Ile501Ser) (rs587780679)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000122971 SCV000166245 uncertain significance Hereditary nonpolyposis colorectal neoplasms 2019-08-13 criteria provided, single submitter clinical testing This sequence change replaces isoleucine with serine at codon 501 of the MLH1 protein (p.Ile501Ser). The isoleucine residue is moderately conserved and there is a large physicochemical difference between isoleucine and serine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individuals affected with clinical features of Lynch syndrome (Invitae) and breast cancer (PMID: 29484706). ClinVar contains an entry for this variant (Variation ID: 135847). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV000217500 SCV000277910 uncertain significance Hereditary cancer-predisposing syndrome 2018-05-22 criteria provided, single submitter clinical testing Insufficient evidence
GeneDx RCV000486481 SCV000573032 uncertain significance not provided 2018-10-29 criteria provided, single submitter clinical testing This variant is denoted MLH1 c.1502T>G at the cDNA level, p.Ile501Ser (I501S) at the protein level, and results in the change of an Isoleucine to a Serine (ATT>AGT). This variant has not, to our knowledge, been published in the literature as a pathogenic or benign germline variant. MLH1 Ile501Ser was not observed in large population cohorts (Lek 2016). This variant is located in the region of interaction with EXO1 as well as PMS2/MLH3/PMS1 (Raevaara 2005, Kansikas 2011, Andersen 2012). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether MLH1 Ile501Ser is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Color RCV000217500 SCV000689819 uncertain significance Hereditary cancer-predisposing syndrome 2020-03-03 criteria provided, single submitter clinical testing
Counsyl RCV000662470 SCV000784962 uncertain significance Lynch syndrome II 2017-02-22 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.